Duke Cancer Institute's Cellular and Gene Therapy program creates, develops, and delivers the full potential of cell and gene therapy, revolutionizing what is possible for patients.
Since treating our first patient with chimeric antigen receptor (CAR) T-cell therapy in 2018, Duke has expanded our selection of available treatments and invested significant resources to grow and evolve the program with patient safety and holistic care at the forefront, putting patient safety and holistic care always at the forefront.
View the full breadth of commercial products available at Duke Health.
Duke has a uniquely experienced, expert group of clinical providers, including but not limited to world-renowned physicians and physician investigators. Expertly trained and skilled stem cell transplantation and cell therapy nurse coordinators, cell infusion, pheresis nurses and quality and regulatory staff enable our safe and effective patient treatments.
Expertise and Experience Across Disciplines
Our team of more than 20 physicians specializing in cell and gene therapies treat more than 100 patients each year and lead clinical trials for emerging therapies that are shaping the future of treatment for these complex diseases. Patients receive multidisciplinary care from our team of specialists, from nurses and pharmacists to hematologists and palliative care providers
End-to-End Support for Patients and Families
Care coordinators and highly skilled nurses serve as a reliable resource from the first point of contact to the last day of follow-up post-treatment, delivering concierge-level care and support to patients, caregivers and referring providers to ensure seamless communication and streamlined access to care.
Support services are available to patients and families during treatment, including assistance with insurance coverage, local housing, counseling and more. We collaborate with referring providers to ensure that patients receive the advanced treatments they need and experience a continuity of care once they return to their primary physician.
Life-Saving Stem Cell Transplants Now an Option for More People with Blood Cancer
Leukemia
Lymphoma
Melanoma
If you are a physician, nurse, or referring practice, please contact our CGT team at 919-684-7115 or cartatduke@duke.edu.
jacob.keller@duke.edu
919-660-3233
Professor of Medicine
Lauren Jones
Team Lead, Cellular and Gene Therapy Nurse Coordination
Jacob Keller
Administrative Director
Assistant Professor of Medicine
Professor of Pediatrics
Chief of Hematologic Malignancies and Cellular Therapy
The Cellular and Gene Therapy program provides specialized support for cell and gene therapy trials, ensuring early alignment on budget
and shared resource needs while streamlining onboarding to prevent future logistical challenges.
For more than a decade, DCI has been leading clinical trials for emerging cellular and gene therapies that are shaping the future of treatment for these complex diseases. Our active clinical trials examine investigational cellular therapies and supportive care for cancer patients, and multiple other studies evaluate novel cell therapies for non-malignant diseases.
Duke has long been a leader in therapy development. DCI's Cellular and Gene Therapy program provides specialized support for cell and gene therapy trials, ensuring early alignment on budget and shared resource needs while streamlining onboarding to prevent future logistical challenges.
Our research promotes the development of Investigator-Initiated Trials (IITs) and industry-sponsored trials, while simultaneously providing an independent Clinical Research Unit (CRU) dedicated to supporting this work. This infrastructure accelerates the translation of basic science into clinical breakthroughs.
" These clinical trials offer opportunities for patients to try treatments that are not available on the market, therapies that might be more effective or, for some patients, we’re giving them options when a treatment isn’t available otherwise.
"